Trial · NCT07385001
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
NCT07385001, Phase 1, Phase 2, Recruiting, Tang-Du Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC. Trials, record NCT07385001. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07385001
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
- NCT number
- NCT07385001
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Tang-Du Hospital
- Conditions
- Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant
- Interventions
- AK112, AK112, AK112 + Neoadjuvant chemotherapy
- First posted
- 2026-02-03
- Last updated
- 2026-02-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | DLT | 1 year | Dose-limiting toxicity |
| Primary | Incidence and Severity of Adverse Events | 1 year | |
| Primary | MTD | 1 year | Maximum tolerated dose |
| Primary | RP2D | 1 year | Recommended Phase II Dose |
| Primary | Major Pathologic Response(MPR) | up to 2 years | Defined as a residual viable tumor percentage (RVT%) ≤ 10% |
| Secondary | Objective response rate (ORR) by RECIST v1.1 | Up to 2 years | ORR is defined as the proportion of subjects with confirmed CR or confirmed PR |
| Secondary | Event-Free Survival (EFS) | Up to 2 years | EFS is defined as the time from randomization to the occurrence of any event, including disease progression, treatment discontinuation for any reason, or death. |
| Secondary | Total survival time (OS) | Up to 2 years | OS defined as the time from the first dose to death from any cause |
| Secondary | Adverse Events (AE), Serious Adverse Events (SAE), and Immune-Related Adverse Events (irAE): Incidence and Severity | From the time of informed consent signed through 90 days after the last dose of study drug |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07385001
GET https://conductscience.org/api/trials/v1/NCT07385001/registered